Photoswitchable channel blockers for treatment of blindness

用于治疗失明的光开关通道阻断剂

• 批准号: 8916750
• 负责人: Russell N. Van Gelder
• 金额: $ 97.95万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-09-01 至 2019-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8916750
• 关键词: Animal Model; Blindness; Canis familiaris; Cell Death; Chemicals; Clinical; Clinical Research; Clinical Treatment; Development; Disease; Eye; Generations; Goals; Grant; Health; Human; In Vitro; Inherited; Kinetics; Laboratories; Light; Modeling; Mus; Pharmaceutical Preparations; Photoreceptors; Primates; Principal Investigator; Rattus; Relative (related person); Retina; Retinal; Retinal Degeneration; Safety; Testing; Toxic effect; Toxicology; Visible Radiation; Vision; Voltage-Gated Potassium Channel; Work; age related; behavioral response; blind; channel blockers; efficacy testing; ganglion cell; improved; in vivo; mouse model; pre-clinical; response; restoration; small molecule

DESCRIPTION (provided by applicant): Photoreceptor cell death from age-related or hereditary retinal degeneration remains the leading cause of blindness in the developed world. The inner retina is largely spared in these diseases. Photoswitch chemicals are specific pharmacologic agents whose activity can be modulated using visible light. We propose utilizing this class of compounds as an approach to reverse blindness from outer retinal degeneration. Preliminary work from our laboratories has demonstrated that the photoswitchable voltage gated potassium channel antagonist AAQ is able to restore electrophysiological retinal responses to several mouse models of outer retinal blindness, and is able to restore pupillary light responses and behavioral responses to light in blind mice. However, AAQ has limitations in terms of its wavelength sensitivity, kinetics, and potential toxicity. Two 'second generation' photoswitch compounds, DENAQ and PhENAQ, show improved spectral response, kinetics, and tolerance in the eye. We propose rigorously testing these two compounds against each other in vitro and in in vivo in mouse, rat, dog, and primate models to determine which to take forward into clinical development; propose an in depth analysis of their effects on the primate retina in vitro, in order to understand their potential for rescue of human blindness; and propose performing required preclinical toxicology and efficacy tests with the goal of applying for a new drug application to allow human clinical studies at the conclusion of this grant.

描述（由申请人提供）：在发达国家，与年龄相关或遗传性视网膜变性导致的感光细胞死亡仍然是失明的主要原因。在这些疾病中，内层视网膜在很大程度上幸免于难。光开关化学物质是特定的药理学试剂，其活性可以使用可见光进行调节。我们建议利用这类化合物作为一种方法，以扭转失明的外部视网膜变性。我们实验室的初步工作已经证明，光开关电压门控钾通道拮抗剂AAQ能够恢复几种外视网膜盲小鼠模型的电生理视网膜反应，并且能够恢复盲小鼠的瞳孔光反应和对光的行为反应。然而，AAQ在其波长灵敏度、动力学和潜在毒性方面存在局限性。两种“第二代”光开关化合物DENAQ和PhENAQ在眼睛中显示出改善的光谱响应、动力学和耐受性。我们建议在小鼠、大鼠、狗和灵长类动物模型中严格测试这两种化合物在体外和体内的相互作用，以确定哪种化合物可以进入临床开发;建议深入分析它们在体外对灵长类动物视网膜的作用，以 了解其拯救人类失明的潜力;并建议进行所需的临床前毒理学和疗效测试，目的是申请新药申请，以便在本资助结束时进行人类临床研究。